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Abstract
Background: In cancer, cellular transformation is followed by tumour development. Knowledge
on the mechanisms of transformation, involving activation of proto-oncogenes and inactivation of
tumour-suppressor genes has considerably improved whereas tumour development remains
poorly understood. An interesting way of gaining information on tumour progression mechanisms
would be to identify genes whose expression is altered during tumour formation. We used the
Affymetrix-based DNA microarray technology to analyze gene expression profiles of tumours
derived from rasV12/E1A-transformed mouse embryo fibroblasts in order to identify the genes that
could be involved in tumour development.
Results: Among the 12,000 genes analyzed in this study, only 489 showed altered expression
during tumour development, 213 being up-regulated and 276 down-regulated. The genes
differentially expressed are involved in a variety of cellular functions, including control of
transcription, regulation of mRNA maturation and processing, regulation of protein translation,
activation of interferon-induced genes, intracellular signalling, apoptosis, cell growth, angiogenesis,
cytoskeleton, cell-to-cell interaction, extracellular matrix formation, metabolism and production of
secretory factors.
Conclusions: Some of the genes identified in this work, whose expression is altered upon rasV12/
E1A transformation of MEFs, could be new cancer therapeutic targets.
Background
Cellular transformation is a complex process which
involves activation of proto-oncogenes and inactivation
of tumour-suppressor genes [1]. After transformation, the
cells can generate malignant tumours, by mechanisms
only partly understood yet. It is supposed that some
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modifications in the pattern of gene expression will pro-
mote survival of transformed cells in situ, other modifica-
tions will favour eventual formation of metastases [2], the
capacity to adapt a new microenvironment being of major
importance for successful tumour development and pro-
gression [reviewed in [3]]. Therefore, identification of
genes whose expression is altered during tumour forma-
tion should provide important information on the under-
lying molecular mechanisms. In the present work, we
used the Affymetrix-based DNA microarray technology to
analyze gene expression profiles of tumour-derived from
rasV12/E1A-transformed primary mouse embryonic
fibroblasts (MEFs), in order to identify genes associated
with tumour development.
Results and Discussion
The ras oncogene can transform most immortalized
rodent cells to generate tumour cells, whereas transforma-
tion of primary cells requires either a cooperating onco-
gene or the inactivation of a tumour suppressor gene. The
adenovirus E1A oncogene cooperates with ras to trans-
form primary rodent fibroblasts [4] and injection of ath-
ymic mice with such transformed fibroblasts induces
tumour development. The rasV12/E1A model of tumour
formation was used in this work to analyze genes neces-
sary for tumour progression. This model was chosen
because transformation is induced in a simple and con-
trolled way, avoiding the difficulties of analyzing the mul-
tiple and complex transformation mechanisms observed
in cellular models derived from human tumours. Mouse
embryo fibroblasts (MEFs) were chosen for transforma-
tion by rasV12/E1A to keep the model homogeneous, the
host being the athymic mouse. Because non-transformed
MEFs are unable to induce tumour when injected into ath-
ymic mice, we previously analyzed the change in gene
expression profile induced in MEFs by rasV12/E1A-trans-
formation [5], the idea being that such genetic changes
are, directly or indirectly, responsible for the capacity of
transformed MEFs to form tumours upon injection. As a
follow-up, we used in this work microarray analysis to
compare expression profiles of about 12,000 genes in
rasV12/E1A-transformed MEFs and in the tumours formed
after their injection into nu/nu mice. With Affymetrix
microarray technology, differential expression values
greater than 1.7 are likely to be significant, based on inter-
nal quality control data. We present data that use a more
stringent ratio, restricting our analysis to genes overex-
pressed or under-expressed at least 2.0 fold in tumours,
compared to the parent rasV12/E1A-transformed fibrob-
lasts. Most striking findings are summarized below while
complete data are presented in Tables 1 and 2 (see addi-
tional files 1 and 2), values being the average of three sep-
arate experiments. Among the 12,000 genes analyzed in
this study, only 489 (4%) showed altered expression
upon tumour development. Whereas 213 were up-regu-
lated, 276 were down-regulated. Sixty seven genes encode
ESTs. For 10 genes, expression data from microarrays were
confirmed (Figure 1) by semiquantitative RT-PCR (see
Material and Methods).
It is noteworthy that, to form tumours, transformed cells
require the vicinity of blood vessels and components of
the stroma, fibroblasts and inflammatory cells. Conse-
quently, mRNA quantified in our system will come from
transformed cells growing within the tumour and from
stromal cells provided by the host. For example, mRNAs
for haemoglobin, selectin or immunoglobulin heavy
chain (V10 family) will very probably originate from
erythrocytes, endothelium and leucocytes respectively.
Gene transcription, mRNA processing and translation-
associated genes
Down-regulation was observed for some DNA-binding
proteins and transcriptional factors such as zinc finger
protein 36, C3H type-like 2, forkhead box M1, T-box 14,
SET and MYND domain containing 2, sine oculis-related
homeobox 1 homolog (Drosophila), liver-specific bHLH-
Zip transcription factor, deformed epidermal autoregula-
tory factor 1 homolog (Drosophila), HMG box Bromodo-
main (5 domains) Zinc finger C2H2 type, BTB (POZ)
domain containing 14A, Jun oncogene, general transcrip-
tion factor III A, MYB binding protein (P160) 1a, general
transcription factor II H polypeptide 1, transcription fac-
tor Dp 1, myeloblastosis oncogene-like 2, general tran-
scription factor IIF polypeptide 1, v-ets erythroblastosis
virus E26 oncogene homolog 1 (avian), transcriptional
regulator SIN3B homolog (yeast), RNA polymerase I tran-
scription factor RRN3, Kruppel-like factor 5, general tran-
scription factor III C 1, nucleosome assembly protein 1-
like 1, general transcription factor IIB and transformation
related protein 53 (p53) whereas CCR4-NOT transcrip-
tion complex subunit 7, transcription factor 15, dimeriza-
tion cofactor of hepatocyte nuclear factor 1 alpha (TCF1),
chromobox homolog 3 (Drosophila HP1 gamma), ets
variant gene 1, basic helix-loop-helix domain containing
class B2, pre-B-cell colony-enhancing factor 1, homeo box
C6, BTB (POZ) domain containing 1, zinc finger protein
37, enhancer of zeste homolog 1 (Drosophila) and AT
rich interactive domain 3B (Bright like) were up-regu-
lated.
A number of genes involved in RNA maturation, protein
translation, processing and secretion were down-regu-
lated in tumours, such as eukaryotic translation initiation
factor 4 gamma 1, ER degradation enhancer mannosidase
alpha-like 1, paraspeckle protein 1, CUG triplet repeat,
RNA binding protein 1, copper chaperone for superoxide
dismutase, splicing factor arginine/serine-rich 2 interact-
ing protein, ribosomal protein S6 kinase polypeptide 4,
sorting nexin 14, sorting nexin 17, elongation protein 3
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homolog (S. cerevisiae), eukaryotic translation initiation
factor 5B, peptidylprolyl isomerase F (cyclophilin F),
ubiquitin-conjugating enzyme E2S, DnaJ homolog sub-
family C member 3, SEC14-like 1 (S. cerevisiae), mito-
chondrial ribosomal protein L18, mitochondrial
isoleucine tRNA synthetase, brix domain-containing pro-
tein, proteasome 26S subunit non-ATPase 1, COP9 subu-
nit 5, small nuclear ribonucleoprotein polypeptide A, heat
shock protein 105, heat shock protein 1, ribosome-bind-
ing protein p34, splicing factor 3b subunit 1, proteasome
26S subunit non-ATPase 7, mitochondrial processing
peptidase beta, translocating chain-associating membrane
protein 1, mitochondrial ribosomal protein L44, mito-
chondrial ribosomal protein S25, mitochondrial ribos-
omal protein S10, eukaryotic translation initiation factor
3 subunit 1 alpha, eukaryotic translation initiation factor
1A, COP9 subunit 2, RNA-binding region (RNP1, RRM)
containing 1, DNAJ domain-containing and Der1-like
family protein, whereas only 7 genes from this group were
up-regulated including ubiquitin specific protease 18,
proteosome subunit beta type 8, heterogeneous nuclear
ribonucleoprotein U, ERO1-like (S. cerevisiae), proteas-
ome subunit beta type 10, hnRNP-associated with lethal
yellow and peptidylprolyl isomerase (cyclophilin)-like 2.
Altogether these results show that transcriptional factors
and DNA-binding proteins involved in transcription, as
well as proteins involved in RNA maturation, protein
Confirmation of microarray results by sequantitative RT-PCR analysisFigure 1
Confirmation of microarray results by sequantitative RT-PCR analysis. Total RNA was isolated from primary embryo fibrob-
lasts (MEFs), rasV12/E1A MEFs and rasV12/E1A MEF-induced tumours. In these three preparations, mRNA encoding arginase 1, 
bone morphogenetic protein 10, cathepsin S, insulin-like growth factor binding protein 4, interferon stimulated gene 12, serum 
deprivation response, thrombomodulin, adenylate kinase 1, connective tissue growth factor and S100 calcium binding protein 
A11 were amplified by RT-PCR as described in Material and Methods section.
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translation, processing and secretion are preferentially
down regulated during tumour development, suggesting
that protein synthesis is less active in tumours than in
transformed cells in vitro.
Interferon-induced genes
It is interesting to note that 11 genes activated by inter-
feron were found up-regulated in tumours from 3.2 to
44.6 folds. They comprise the interferon stimulated gene
12 and genes encoding the interferon-induced protein
with tetratricopeptide repeats 1, the interferon-induced
protein with tetratricopeptide repeats 3, the interferon
regulatory factor 7, the interferon alpha-inducible pro-
tein, the interferon consensus sequence binding protein 1,
the interferon-inducible GTPase, the interferon induced
transmembrane protein 2, the interferon gamma induced
GTPase, the interferon-g induced GTPase and the inter-
feron gamma-inducible protein 16
Genes encoding signalling factors
Expression of several genes involved in signalling was
modified in tumours. Among up-regulated were genes
encoding the TYRO protein tyrosine kinase binding pro-
tein, ADP-ribosylation factor-like 4, ARF-GAP RHO-GAP
ankyrin repeat and pleckstrin homology domains-con-
taining protein 3, guanosine diphosphate dissociation
inhibitor 2, SET domain bifurcated 1, acid phosphatase 5,
guanylate nucleotide binding protein 3, SH3-domain
GRB2-like 2, rap2 interacting protein x, TGFB inducible
early growth response 1, pleckstrin homology domain
containing family A (phosphoinositide binding specific)
member 1, A kinase (PRKA) anchor protein 8, PDZ and
LIM domain 4, protein tyrosine phosphatase non-recep-
tor type 13, calcium and integrin binding family member
2, diaphanous homolog 2 (Drosophila), SH3-domain
GRB2-like 3, Janus kinase 3, dual specificity phosphatase
9, Nik related kinase, synaptojanin 2, zinc finger RAN-
binding domain containing 1, inositol hexaphosphate
kinase 1, spleen tyrosine kinase, ribitol kinase putative, B
lymphoid kinase, DEAD box polypeptide 27, mitogen
activated protein kinase kinase kinase kinase 1, tumor-
associated calcium signal transducer 1 and ral guanine
nucleotide dissociation stimulator. Among down-regu-
lated during tumour development where genes encoding
adenylate kinase 1, serum deprivation response, ATP-
binding cassette sub-family F member 2, protein kinase C
alpha, RIO kinase 1 homolog (yeast), protein phos-
phatase 1 regulatory (inhibitor) subunit 2, phosphotidyli-
nositol transfer protein beta, RAN GTPase activating
protein 1, v-crk sarcoma virus CT10 oncogene homolog
(avian)-like, serum/glucocorticoid regulated kinase,
DEAD box polypeptide 48, nucleolar GTPase, calcium/
calmodulin-dependent protein kinase II delta, cellular
retinoic acid binding protein I, AFG3(ATPase family gene
3)-like 1 homolog (yeast), transforming growth factor
beta regulated gene 4, enabled homolog (Drosophila),
Rho GDP dissociation inhibitor gamma, S100 calcium
binding protein A11 (calizzarin), cornichon homolog
(Drosophila), butyrate-induced transcript 1, phosphati-
dylinositol 3-kinase regulatory subunit polypeptide 1
(p85 alpha), mitogen activated protein kinase 1, IQ motif
containing GTPase activating protein 1, protein kinase C
epsilon, transducin (beta)-like 3, serine/threonine kinase
16, thymoma viral proto-oncogene 1, ATP-binding cas-
sette sub-family B (MDR/TAP) member 7, protein phos-
phatase 1 regulatory (inhibitor) subunit 7, dual specificity
phosphatase 1, Rho-associated coiled-coil forming kinase
2, acid phosphatase 1 soluble, PAK1 interacting protein 1,
RAN binding protein 1, dual specificity phosphatase 16,
RAB23 member RAS oncogene family, WD repeat domain
26, PDZ and LIM domain 1 (elfin) and mitogen activated
protein kinase kinase 4.
Apoptosis-related genes
The rasV12/E1A-transformed MEFs are very sensitive to
apoptosis in vitro [6] whereas, on the contrary, these cells
do not show signs of apoptosis in tumours as judged by
microscopic analysis. A possible explanation is provided
by the observation that many proapoptotic genes are
down-regulated in tumours, such as growth arrest and
DNA-damage-inducible 45 beta, wild-type p53-induced
gene 1, Bcl2-associated X protein, programmed cell death
2, TP53 apoptosis effector, programmed cell death 6 inter-
acting protein, apoptotic chromatin condensation
inducer 1, cell division cycle and apoptosis regulator 1,
large tumour suppressor 2 and caspase 7 and several antia-
poptotic genes are up-regulated, including genes encoding
the spermatogenesis apoptosis-related protein and BCL2/
adenovirus E1B 19kDa-interacting protein 1 (NIP3).
Cell growth-involved genes
Another interesting point to be underscored is that expres-
sion of many cell growth-related genes was found
decreased in tumours, whereas none of them was up-reg-
ulated. Among up-regulated genes were those coding for
he bone morphogenetic protein 10, cytokine receptor-like
factor 1, insulin-like growth factor binding protein 4,
ephrin A2, schlafen 4, early growth response 2, retinoblas-
toma-associated factor 600, receptor tyrosine kinase-like
orphan receptor 2, cyclin-dependent kinase 7 (homolog
of Xenopus MO15 cdk-activating kinase), inhibitor of
growth family member 4 and neoplastic progression 1
were up-regulated and connective tissue growth factor,
ephrin B2, neural proliferation differentiation and control
gene 1, nerve growth factor beta, Eph receptor A2, neo-
plastic progression 3, cyclin G1, bone morphogenetic pro-
tein receptor type 1A, cell division cycle 34 homolog (S.
cerevisiae), cyclin-dependent kinase inhibitor 1A (p21),
SGT1 suppressor of G2 allele of SKP1 homolog (S. cerevi-
siae), nuclear casein kinase and cyclin-dependent kinase
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substrate, G two S phase expressed protein 1, prohibitin,
nucleostemin, CDK2-associated protein 1 and block of
proliferation 1 This is not a surprise since transformed
cells grow more rapidly in vitro than during tumour
development.
Angiogenesis-involved genes
Some proangiogenic genes such as angiopoietin-like 4,
selectin, endothelin 1, angiopoietin 2 and endothelial
PAS domain protein 1 were up-regulated during tumour
growth whereas the antiangiogenic factor thrombospon-
din 1 was found to be down regulated. Surprisingly, the
proangiogenic endothelial cell growth factor 1 (platelet-
derived) and the angiomotin like 2 were found down-reg-
ulated.
Cytoskeleton and cell-to-cell contact genes
Expression of some genes involved in cytoskeleton and
cell-to-cell contact was modified in tumours. mRNAs
encoding junctophilin 3, fibrillin 2, plexin A3, ARP1
actin-related protein 1 homolog A, MYOSIN-IXA
homolog, myosin IB, tubulin alpha 1, cadherin 3, integrin
beta 5, dynamin and stathmin-like 4 genes were up-regu-
lated whereas mRNAs encoding MAP/microtubule affin-
ity-regulating kinase 2, nucleoporin 54 kDa, smooth
muscle cell associated protein-1, plakophilin 2, annexin
A3, myosin X, ARP1 actin-related protein 1 homolog B
(yeast), follistatin, golgi associated gamma adaptin ear
containing ARF binding protein 2, filamin beta, vinculin,
cytoskeleton-associated protein 1, annexin A11, lamin A,
cortactin, pericentrin 2, gap junction membrane channel
protein alpha 1, importin 4, nucleolar protein 5, exportin
7, vinculin, actinin alpha 1, nucleoporin 88, fibulin 2 and
CD44 antigen were down regulated.
Extracellular matrix compounds
In cancer, transformed and mesenchymal cells synthesize
and secrete several compounds which participate to
tumour organization. In tumour cells, genes encoding the
procollagen type XVIII alpha 1, Nice-4 protein homolog
isoform 1, glycophorin A, collagen type V alpha 1 and
procollagen type VI alpha 1 were up-regulated whereas, to
our surprise, procollagen type V alpha 2 was found down
regulated.
Metabolic enzymes and secretory factors
Finally, an interesting finding is that the majority of genes
encoding enzymes involved in metabolism were down
regulated in tumours whereas the majority of secretory
factors or their receptors were up-regulated (see additional
files 1 and 2) suggesting some reduction of intracellular
metabolic activity and increased signal exchanges during
tumour formation.
Conclusion
The microenvironment of the metastatic cancer cell and
the interaction between these cells and the stroma play
critical roles in tumour development and progression.
However, the molecular mechanisms and genes involved
in tumour development remain largely unidentified. In
the experimental model of tumour formation used in this
study, we identified 489 genes whose expression is modi-
fied during tumour formation. Among them, 213 were
up-regulated and 276 were down-regulated. These genes
are involved in a variety of cellular functions, including
control of transcription, mRNA processing, regulation of
translation, activation of some interferon-induced genes,
intracellular signalling, apoptosis, cell growth, angiogen-
esis, cytoskeleton, cell adhesion, extracellular matrix for-
mation, metabolism and production of secretory factors.
These results can be interpreted in two ways i/ many cellu-
lar functions need to be adapted to allow successful
tumour development or ii/ successful tumour formation
has induced changes in gene expression. In fact, both
interpretations are probably correct but the important
point is that among them are found the genes involved in
adaptation of the cancer cell to a new environment, which
are potential targets for cancer therapy. This study there-
fore suggests that, after screening ~12,000 genes, the most
interesting candidates for clinical applications are among
the 213 genes up-regulated in the tumour.
Material and Methods
Transformation of MEFs by retroviral infection
Primary embryo fibroblasts were isolated from 14.5 day-
old SV129J mouse embryos and grown in Dulbecco's
modified Eagle's medium supplemented with 10% foetal
calf serum as previously described [7]. We transduced
MEFs with the pBabe-rasV12/E1A retroviral vector which
expresses both the rasV12 mutated protein and the E1A
oncogene to obtain transformed fibroblasts. pBabe-
rasV12/E1A plasmids were obtained from S. Lowe. Bosc 23
ecotropic packaging (106) cells were plated in a 6-well
plate, incubated for 24 hr, and then transfected with PEI
with 5 µg of retroviral plasmid. After 48 hr, the medium
containing the virus was filtered (0.45 µm filter, Milli-
pore) to obtain the retroviral supernatant. MEFs were
plated at 2 × 105 cells per 35 mm dish and incubated over-
night. For infection, the culture medium was replaced by
an appropriate mix of the retroviral supernatant and cul-
ture medium (V/V), supplemented with 4 µg/ml poly-
brene (Sigma), and cells were incubated at 37°C.
Transformation of MEFs by the pBabe-rasV12/E1A retrovi-
ral vector was evaluated by examining changes in their
morphological aspect, by quantifying expression of the
RAS protein by western blot, by monitoring cell prolifera-
tion, colony formation in soft-agar and tumours in nude
mice as previously described [7].
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Tumour induction in athymic mice
Suspensions of the pBabe-rasV12/E1A transformed MEFs
(106/200 µl PBS) were injected subcutaneously into the
flank of male 8 week-old nu/nu mice, and tumours were
allowed to develop for 20 days. Tumours were removed
and stored at -80°C. Microscopical analysis reveals that
tumours contain about 15% of vascular and stromal cells.
Microarray
Total RNA from rasV12/E1A-transformed cells and
tumours from three independent experiments was iso-
lated by Trizol (Gibco-BRL). Twenty µg of total RNA was
converted to cDNA with SuperScript reverse transcriptase
(Gibco-BRL), using T7-oligo-d(T)24 as a primer. Second-
strand synthesis was performed using T4 DNA polymerase
and E. coli DNA ligase followed by blunt ending by T4
polynucleotide kinase. cDNA was isolated by phenol-
chloroform extraction using phase lock gels (Brinkmann).
cDNA was transcribed in vitro using the T7 BioArray High
Yield RNA Transcript Labeling Kit (Enzo Biochem, New
York, N.Y.) to produce biotinylated cRNA. Labelled cRNA
was isolated using an RNeasy Mini Kit column (Qiagen).
Purified cRNA was fragmented to 200–300 mer cRNA
using a fragmentation buffer (100 mM potassium acetate-
30 mM magnesium acetate-40 mM Tris-acetate, pH 8.1),
for 35 min at 94°C. The quality of total RNA, cDNA syn-
thesis, cRNA amplification and cRNA fragmentation was
monitored by micro-capillary electrophoresis (Bioanal-
izer 2100, Agilent Technologies). The cRNA probes were
hybridized to an MG u74Av2 Genechip (Affymetrix, Santa
Clara, CA). Fifteen micrograms of fragmented cRNA was
hybridized for 16 h at 45°C with constant rotation (60
rpm). Microarrays were processed in an Affymetrix Gene-
Chip Fluidic Station 400. Staining was made with strepta-
vidin-conjugated phycoerythrin (SAPE) followed by
amplification with a biotinylated anti-streptavidin anti-
body and a second round of SAPE, and then scanned
using an Agilent GeneArray Scanner (Agilent Technolo-
gies). The signal intensities for the β-actin and GAPDH
genes were used as internal quality controls. The ratio of
fluorescent intensities for the 5' and 3' ends of these
housekeeping genes was <2. Scanned images were ana-
lyzed with the Microarray Suite 5.0 software (Affymetrix).
Validation of gene expression profiles
One microgram of total RNA from primary embryo
fibroblasts, rasV12/E1A transformed MEF and its derived
tumour was subjected to PCR with reverse transcription
using the One Step RT-PCR kit (Promega) according to the
manufacturer's protocol. Selected RNA species were
amplified using the following primers: arginase 1, sense,
5'-gaaaaggccgattcacctgag-3' and antisense, 5'-atgtggcgcat-
tcacagtcac-3'; bone morphogenetic protein 10, sense, 5'-
ggatctggacctggactcaga-3' and antisense, 5'-gaagctttct-
gggaattcttg-3'; cathepsin S, sense, 5'-gaagggctgcgtcact-
gaggt-3' and antisense, 5'-acaccgcttttgtagaagaag-3';
insulin-like growth factor binding protein 4, sense, 5'-
gaaggtgtagagtagaggctc-3' and antisense, 5-ggaccagaat-
ggggccattcc-3'; interferon stimulated gene 12, sense, 5'-
ctcaacatgttgggaacactg-3' and antisense, 5-catctcctgcgtagtct-
gtac-3'; serum deprivation response, sense, 5'-gtctagtat-
tataacctaacc-3' and antisense, 5-aagagtagagagttcgagccc-3';
thrombomodulin, sense, 5'-cagaaatttcaggtaaccaaa-3' and
antisense, 5-tcagctcggcacgaagcacac-3'; adenylate kinase 1,
sense, 5'-cactgggtgccaaggagctgt-3' and antisense, 5-ggcttc-
ctgtgtaatgagacc-3'; connective tissue growth factor, sense,
5'-ggagtcagagccttgtctgtt-3' and antisense, 5-agtcataatcaaa-
gaagcagc-3'; and S100 calcium binding protein A11,
sense, 5'-gctgttttccaaaagtacagc-3' and antisense, 5-cgcttct-
gggaagtttggatg-3'. Reverse transcription was carried out 45
min at 48°C followed by 25–32 cycles of PCR, each cycle
consisting in a denaturing step for 1 min at 94°C, an
annealing step for 2 min at 56°C, and a polymerization
step for 2 min at 72°C. PCR products were separated on a
1.0% agarose gel containing ethidium bromide and pho-
tographed under ultraviolet light.
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